1: Ke Z, Hou X, Jia XB. Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D. Drug Des Devel Ther. 2016 Jun 28;10:2049-60. doi: 10.2147/DDDT.S106356. eCollection 2016. 2: Wu J, Tan Z, Chen J, Dong C. Cyclovirobuxine D Inhibits Cell Proliferation and Induces Mitochondria-Mediated Apoptosis in Human Gastric Cancer Cells. Molecules. 2015 Nov 19;20(11):20659-68. doi: 10.3390/molecules201119729. doi: 10.1016/j.jchromb.2015.08.022. Epub 2015 Aug 24. doi: 10.1155/2015/151972. Epub 2015 May 14. 5: Xu YN, Wang Y, Bo S, Jiang Y, Liu XD, Shen XC. [Ameliorated effects of cyclovirobuxine D on oxidative stress and energy metabolism in experimental cardiac injured rats induced by sympathetic overactivity in vivo]. Zhong Yao Cai. 2014 Jul;37(7):1213-7. Chinese. Epub 2014 Apr 24. doi: 10.1016/j.saa.2014.03.007. Epub 2014 Mar 20. doi: 10.1016/j.fitote.2012.09.019. Epub 2012 Sep 27. doi: 10.1016/j.fitote.2011.04.016. Epub 2011 May 6. doi: 10.1016/j.ejphar.2011.03.039. Epub 2011 Apr 12. Chinese. Chinese. Epub 2006 Jul 5. Epub 2006 Jun 9. Chinese. Chinese. Chinese. Chinese.
合成参考文献
参考文献:10.1016/j.jpba.2006.04.025 摘要:Yu P, Zou L, Liu W, Wu C, Sun D, Xu J, Rao J, Yang Q. High performance liquid chromatography – tandem mass spectrometric determination of cyclovirobuxine D in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 2006 Oct;42(4):488–93. doi: 10.1016/j.jpba.2006.04.025.